home / stock / ocgn / ocgn news

OCGN News and Press, Ocugen, Inc. From 04/29/24

Stock Information
Company Name: Ocugen, Inc.
Stock Symbol: OCGN
Market: NYSE
Website: ocugen.com
Menu
OCGN OCGN Quote OCGN Short OCGN News OCGN Articles OCGN Message Board
Get OCGN Alerts

News, Short Squeeze, Breakout and More Instantly...
OCGN - Can Ocugen Stock Keep Churning Higher?

2024-04-29 08:30:00 ET Since the start of the year, Ocugen (NASDAQ: OCGN) has been on fire. The biotech's shares have gained an eye-popping 122%, far surpassing the performance of small-cap growth stocks this year. (See the following graph.) What's fueling this rally? Is Ocugen's st...
OCGN - Ocugen Announces OCU400-Modifier Gene Therapy-Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024

MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Benjamin Bakall, MD, PhD, Director of Clinical Res...

OCGN - UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifi...

OCGN - Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifi...
OCGN - SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Ocugen To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 21, 2024) - Faruqi & Faruqi, LLP, a leading national se...

OCGN - Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value

2024-04-19 17:05:07 ET Summary Ocugen, Inc. expects preliminary safety/efficacy data from phase 1/2 study, using OCU-410 for the treatment of patients with GA, in 2024. Preliminary safety/efficacy data from phase 1/2 study, using OCU-401ST for the treatment of patients with Starga...

OCGN - Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410-A Modifier Gene Therapy

MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete...
OCGN - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Ocugen To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 19, 2024) - Faruqi & Faruqi, LLP, a leading national se...

OCGN - Ocugen stock jumps after $175M securities filing

2024-04-18 06:21:01 ET Read the full article on Seeking Alpha For further details see: Ocugen stock jumps after $175M securities filing

OCGN - DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Ocugen To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 14, 2024) - Faruqi & Faruqi, LLP, a leading national se...
Previous 10 Next 10